ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib

Abstract Background ROS1 rearrangements are validated drivers in lung cancer, which have been identified in a small subset (1–2%) of patients with non-small cell lung cancer (NSCLC). To date, 18 fusion genes of ROS1 have been identified in NSCLC. The ALK inhibitor (crizotinib) exhibits therapeutic e...

Full description

Bibliographic Details
Main Authors: Shuguang Xu, Wenxian Wang, Chunwei Xu, Xingliang Li, Junhui Ye, Youcai Zhu, Ting Ge
Format: Article
Language:English
Published: BMC 2019-08-01
Series:BMC Cancer
Subjects:
Lung adenocarcinoma
NGS
ROS1 rearrangement
Online Access:http://link.springer.com/article/10.1186/s12885-019-5948-y

Internet

http://link.springer.com/article/10.1186/s12885-019-5948-y

Similar Items